"This is a blatant attempt at rent-seeking by an obvious vested interest. We know that the pharmaceutical industry has been lobbying hard to hamper the growth of e-cigarettes so it comes as no surprise to find Glaxo using the tired old gateway argument. The truth is that e-cigarettes will only "seriously disadvantage" the NRT market if they work better as quitting aids. In my experience—and the experience of countless other people—e-cigarettes are much better substitutes for smoking. If they were really a "gateway" to smoking, e-cigarettes would be good for companies like Glaxo as they would create more smokers (NRT companies need there to be smokers just as much as cigarette companies do)."

Hartge et al. exactly the same result as Wynder's group: "Our data indicated that people who have only smoked unfiltered cigarettes have higher risks."

Yesterday, I explained that the of electronic cigarettes by Stan Glantz and colleagues published this week in the journal Circulation is because it draws conclusions about the efficacy of e-cigarettes for smoking cessation from studies that were not designed to measure such effects in the first place. These studies did not examine smoking cessation rates among a cohort of smokers who were identified at baseline as using e-cigarettes with the intention of quitting smoking. Moreover, smokers who use e-cigarettes are likely more heavily addicted to nicotine and may be more resistant to quitting, thus making inferences about cessation effectiveness from these studies inappropriate.

These flaws are also noted by Dr. Robert West, director of tobacco research at University College London, who that: "the study was not able to assess whether or not for cancer patients who smoke using an e-cigarette to try and quit is beneficial "because the sample could consist of e-cigarette users who had already failed in a quit attempt, so all those who would have succeeded already would be ruled out"."

LAST：US Made eLiquid - Killa Vanilla |NEXT：Mini Electronic Atomizer Cartridges J-S1 PCC